VYNE Therapeutics Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $570,000 | $501,000 | $424,000 | $477,000 | $931,000 |
| Operating income | -$29.7M | -$43.6M | -$29.3M | -$34.3M | -$38.9M |
| Cost of revenue | — | — | — | — | $3.3M |
| Cash from operations | -$33.1M | -$34.0M | -$25.3M | -$29.2M | -$56.4M |
| Capital expenditure | $0 | $117,000 | $0 | — | $0 |
| Free cash flow | -$33.1M | -$34.1M | -$25.3M | — | -$56.4M |
| Impairments | — | — | — | — | $0 |
| Total assets | $30.2M | $66.9M | $97.7M | $40.8M | $67.0M |
| Total liabilities | $2.4M | $14.8M | $8.9M | $9.3M | $18.4M |
Shares outstanding 33.4M · Free float 87.3%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.